EPH150 Post-Market Safety Assessment Associated with JAK Inhibitors of Xeljanz, Olumiant, and Rinvoq Using Faers Database from 2012 to 2022
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.978
https://www.valueinhealthjournal.com/article/S1098-3015(24)01093-3/fulltext
Title :
EPH150 Post-Market Safety Assessment Associated with JAK Inhibitors of Xeljanz, Olumiant, and Rinvoq Using Faers Database from 2012 to 2022
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)01093-3&doi=10.1016/j.jval.2024.03.978
First page :
Section Title :
Open access? :
No
Section Order :
10415